Emerging Trends Influencing The Growth Of The Genomic Biomarker Market: Technological Advances In Genomic Biomarkers

The Genomic Biomarker Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

How Big Is the Genomic Biomarker Market Size Expected to Be by 2034?
The size of the genomic biomarker market has witnessed swift expansion in the recent past. It is slated to expand from a valuation of $8.4 billion in 2024 to reach $9.9 billion by 2025, marking a compound annual growth rate (CAGR) of 18.0%. The previous growth can be linked to increased awareness about genetic disorders, surging demand for targeted therapies, rising use of big data in genomics, expansion of global genomic databases, and an increase in the count of biomarker-centred clinical trials.

The market size for genomic biomarkers is anticipated to experience a quick growth surge in the upcoming years, escalating to $18.93 billion by 2029 with a compound annual growth rate (CAGR) of 17.6%. This expected growth during the forecast period can be credited to the increasing emphasis on accessible personalized medications, the escalating incidents of cardiovascular diseases, the rise in the number of patients dealing with neurological disorders, increased investments funnelled into genomic research, and the widening acceptance of personalized nutrition. The prediction period will likely be characterized by significant trends including technological progression, digital healthcare, the rise of artificial intelligence and machine learning, along with the advancement of personalized medicine.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20557

What Are the Emerging Segments Within the Genomic Biomarker Market?
The genomic biomarker market covered in this report is segmented -

1) By Type: Predictive Biomarkers, Prognostic Biomarkers
2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications
3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility
4) By End-User: Hospitals, Diagnostic Centers, Research Laboratories, Other End Users

Subsegments:
1) By Predictive Biomarkers: Genetic Biomarkers For Disease Susceptibility, Pharmacogenomic Biomarkers For Drug Response, Early Detection Biomarkers For Disease Prediction, Biomarkers For Treatment Response Prediction
2) By Prognostic Biomarkers: Biomarkers For Disease Progression, Biomarkers For Outcome Prediction, Survival And Recurrence Biomarkers, Biomarkers For Treatment Efficacy And Prognosis

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20557&type=smp

What Long-Term Drivers Are Shaping Genomic Biomarker Market Trends?
The rise in chronic disease occurrence is seen as a key driver for the genomic biomarker market's expansion. Chronic illnesses are persistent and often slowly developing health conditions. The escalating presence of these diseases can be attributed to aging populations and the growth in lifestyle diseases such as obesity and diabetes. Genomic biomarkers offer an avenue to address chronic diseases with a strategy of early detection and personalized prevention. They identify genetic tendencies and adapt interventions accordingly. Such a proactive method reduces disease prevalence by concentrating on those individuals with a higher risk before the disease develops. For example, as reported by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, in September 2023, every year, 41 million deaths globally, or 74% of all deaths, are chronic disease-related. This encompasses 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Thus, the escalating presence of chronic diseases fuels the growth of genomic biomarkers.

Who Are the Top Competitors in Key Genomic Biomarker Market Segments?
Major companies operating in the genomic biomarker market are Pfizer Inc., Roche Diagnostics, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Foundation Medicine Inc., QIAGEN N.V., Almac Group Ltd., Myriad Genetics Inc., Invitae Inc., Guardant Health Inc., Novogene Inc., Twist Bioscience Corp., NanoString Technologies Inc., Quanterix Corp., Personalis Inc., GENEWIZ Inc., Agena Bioscience Inc., Creative Diagnostics Ltd., OncoDNA SA, Genome Life Sciences Ltd., Epigenomics AG.

What Ampoule Bottle Market Trends Are Gaining Traction Across Different Segments?
The genomic biomarker market's key players are focusing on producing cutting-edge products like advanced liquid biopsy assays to facilitate complete genomic profiling of solid tumors. A liquid biopsy assay is a test that detects and tracks cancer by examining genetic material, mainly circulating tumor DNA (ctDNA), from a blood specimen. Detecting genomic biomarkers can disclose information on specific mutations, gene expression patterns, or other genetic changes related to cancer. For example, in November 2023, Illumina Inc., a biotech firm from the United States, unveiled its advanced liquid biopsy assay, the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2). This assay, designed for exhaustive genomic profiling of solid tumors, boosts analytical sensitivity by identifying low-frequency variants using only 20 ng of cell-free DNA, a significant reduction from 30 ng. This assay can produce results in less than four days, which is substantially faster than traditional methods. The simplified process and upcoming automation are set to make lab integration easier and improve efficiency.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/genomic-biomarker-global-market-report

Which Regions Are Becoming Hubs for Genomic Biomarker Market Innovation?
North America was the largest region in the genomic biomarker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Genomic Biomarker Market?
2. What is the CAGR expected in the Genomic Biomarker Market?
3. What Are the Key Innovations Transforming the Genomic Biomarker Industry?
4. Which Region Is Leading the Genomic Biomarker Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the genomic biomarker market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.